News & Publicity
News & Publicity
- Apr. 22, 2021 | OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
- Oct. 07, 2020 | OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
- Jul. 08, 2020 | OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for the Treatment of Major Depressive and Generalized Anxiety Disorder
- Jan. 08, 2020 | OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
- Nov. 20, 2019 | OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine
- Dec. 03, 2019 | OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder
- Illinois Small Business Development Center Network – WEEKLY CONNECTION
- The Business Journals – Bob Buford/American City Journal
- WGNtv – “Chicago-area drug company uses half its profits to fight epilepsy”
- The Business Journals – “A new business model designed to make a difference”